Welcome to RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers (RhAPP). In this episode, host Amanda Mixon, PA-C, kicks off a three-part series exploring some of the most impactful updates in psoriatic arthritis (PsA) from the 2024 ACR Convergence meeting. Joining Amanda is Daric Mueller, PA-C, who shares expert insights on emerging therapies, including zazocitinib (TAK-279), a selective TYK2 inhibitor showing promising results in both joint and skin outcomes for PsA.

Together, Amanda and Daric review key data from several abstracts—highlighting oral treatment options, the significance of dosage on efficacy, and the potential advantages of TYK2 inhibition over JAK inhibitors. They also examine results from the FOReMOST trial, evaluating apremilast in patients with early, oligoarticular PsA—a subgroup often underrepresented in clinical studies.

This episode offers practical takeaways for advanced practice providers managing PsA, emphasizing the growing importance of precision medicine and individualized treatment plans. Whether you're navigating treatment for mild disease or considering alternatives for patients with multiple therapy failures, this conversation will help you stay up to date with the evolving PsA landscape.

Don’t forget to subscribe so you don’t miss Part 2 of our ACR Convergence PsA breakdown!

#PsoriaticArthritis #ACRConvergence2024 #TYK2Inhibitor #Apremilast #RheumatologyPodcast #AdvancedPracticeProvider #RhAPP #OralTherapyForPsA #PrecisionMedicine #RheumatologyEducation